AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Advanced Solid Cancers Clinical Trial

Official title:
Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD 1/PD-L1 Inhibitor as Their Most Recent Therapy

Status Completed

Clinical Trial Summary

This is an open-label, Phase 1/2, multicenter study to evaluate the safety, PK, and PD of an anti-CTLA-4 human monoclonal antibody (AGEN1884) in subjects with advanced or refractory cancer and in subjects who have progressed during treatment with a PD-1/PD-L1 inhibitor as their most recent therapy. The phase 1 portion of the study has been completed; It enrolled adult subjects with refractory, advanced cancer in a 3+3 dose escalation cohort. The phase 2 portion consists of up to 60 patients who have progressed during treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Solid Cancers
Advanced Solid Cancers Refractory to PD-1

Clinical Trial Details

NCT number	NCT02694822
Study type	Interventional
Source	Agenus Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	April 2016
Completion date	March 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02792465` - A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT00886782` - A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT03956680` - An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers	Phase 1
Completed	`NCT03512340` - Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers	Phase 1
Terminated	`NCT03254732` - Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers	Phase 1
Terminated	`NCT00337376` - A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers	Phase 1
Completed	`NCT00478101` - Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain	Phase 2
Completed	`NCT01019941` - Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer	Phase 1